Cochrane Review Group

Multiple Sclerosis and Rare Diseases of the CNS

37 systematic reviews in Multiple Sclerosis and Rare Diseases of the CNS ask 448 questions. 11.2% have no studies to answer them, 29.5% rest on very low certainty evidence and 20.6% reach moderate or high certainty.

Reviews

Questions

448

current versions

No studies

11.2%

Moderate or high

20.6%

No studies 50 · 11.2%Ungraded 14 · 3.1%Very low 132 · 29.5%Low 160 · 35.7%Moderate 76 · 17%High 16 · 3.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Multiple Sclerosis and Rare Diseases of the CNS

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Intervention NR Intervention (no. of studies/participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Placebo · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Intervention (no. of studies/participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	RR 0.77 [0.51, 1.18]	1 study · 59 participants	Very low
Intervention NR Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	RR 0.91 [0.58, 1.43]	1 study · 59 participants	Very low
Intervention NR Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	RR 1.21 [0.66, 2.19]	1 participants	Very low
Intervention NR Teriflunomide (Direct evidence; 1 RCT; 1088 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	RR 0.82 [0.71, 0.94]	1 study · 1088 participants	Very low
Intervention NR Placebo · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Intervention (no. of studies/participants) Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Interferon beta‐1b (Betaferon) (Direct evidence; 2 RCTs; 403 participants) Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	RR 0.86 [0.67, 1.11]	1 study · 2 participants	Very low
Intervention NR Placebo Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Intervention (no. of studies and participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane	no estimate extracted	NR	No studies